Published in Diabetes Ther on August 08, 2016
Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases. World J Gastroenterol (2016) 0.76
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Severe hypoglycemia and risks of vascular events and death. N Engl J Med (2010) 8.54
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int (2013) 5.20
Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet (2012) 4.25
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med (2011) 3.13
Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr Pract (2008) 2.29
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol (2007) 2.26
Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care (2006) 2.19
Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case-control study. Nephrol Dial Transplant (2010) 1.65
Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care (2012) 1.63
The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. J Diabetes Complications (2013) 1.50
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab (2008) 1.44
Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol (2007) 1.36
Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab (2011) 1.32
Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol (2007) 1.31
One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab (2012) 1.26
Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract (2011) 1.20
Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab (2011) 1.13
Hypoglycaemia: current management and controversies. Postgrad Med J (2011) 0.98
Effects of sitagliptin beyond glycemic control: focus on quality of life. Cardiovasc Diabetol (2013) 0.97
Indicators for blood glucose control in diabetics with end-stage chronic renal disease: GHb vs. glycated albumin (GA). J Med Invest (2006) 0.96
A review of gliptins for 2014. Expert Opin Pharmacother (2014) 0.95
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol (2013) 0.91
Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial. Diabetes Care (2015) 0.86
The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes. Endocr Pract (2013) 0.84
Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis. PLoS One (2014) 0.84
Is hypoglycemia fear independently associated with health-related quality of life? Health Qual Life Outcomes (2014) 0.82
Hypoglycemia, chronic kidney disease, and diabetes mellitus. Mayo Clin Proc (2014) 0.82
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. Clin J Am Soc Nephrol (2015) 0.81
Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial. Diab Vasc Dis Res (2015) 0.81
Diabetic kidney disease. Nat Rev Dis Prim (2015) 0.81
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. Am J Kidney Dis (2015) 0.79
Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study. Diabetes Ther (2014) 0.79
Complex type 2 diabetes mellitus--management challenges and pitfalls. Aust Fam Physician (2013) 0.78
Novel hypoglycaemic agents: considerations in patients with chronic kidney disease. Nephron Clin Pract (2014) 0.78
Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease. J Clin Endocrinol Metab (2014) 0.78
Understanding the barriers and improving care in type 2 diabetes: Brazilian perspective in time to do more in diabetes. Diabetol Metab Syndr (2017) 0.75
Relationship Between Duration of Type 2 Diabetes and Effectiveness of DPP-4 Inhibitor Versus Sulfonylurea as Add-on Therapy: A Post Hoc Analysis. Diabetes Ther (2017) 0.75
Effect of race and ethnicity on vildagliptin efficacy: a pooled analysis of phase II and III studies. Diabetes Obes Metab (2016) 0.75